Aqueous stability of SB 210661: Kinetics and primary degradation mechanisms of an N-hydroxyurea-containing 5-lipoxygenase inhibitor

Journal of Pharmacy and Pharmacology

Volumn 50, Issue 2, 1998, Pages 127-132

  Mcloughlin, Martin ^a   Kearney, Albert S ^a   Palepu, Nagesh R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABBOTT 79175; LIPOXYGENASE INHIBITOR; SB 210661; UNCLASSIFIED DRUG; ZILEUTON;

AQUEOUS SOLUTION; ARTICLE; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; DATA BASE; DRUG DEGRADATION; DRUG HYDROLYSIS; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IONIC STRENGTH; PH; REACTION ANALYSIS;

EID: 0031937945     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1998.tb06166.x     Document Type: Article

References (14)

1. Adams, J. L., Garigipati, R. S., Sorenson, M., Schmidt, S. J., Brian, W. R., Newton, J. F., Tyrell, K. A., Garver, E., Yodis, L. A., Chabot-Fletcher, M. C., Tzimas, M., Webb, E. F., Breton, J. J., Griswold, D. E. (1996) Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzoruranyl)urea. J. Med. Chem. 39: 5035-5046
2. Albert, A., Serjeant, E. P. (1971) In: Ionization Constants of Acids and Bases. 2nd Edn, Chapman and Hall, Edinburgh, p. 45
3. Alvarez, F. J., Slade, R. T. (1992) Kinetics and mechanism of degradation of zileuton, a potent 5-lipoxygenase inhibitor. Pharm. Res. 9: 1465-1473
4. Bisagni, E., Civier, A., Marquet, J. P. (1975) Furannes et pyrroles disubstitues en 2,3. XVI Synthese de furo[3,2-c] pyranones-4 et nouvelle voie d'access aux furo[3,2-c]pyridines. J. Heterocycl. Chem. 12: 461
5. Chabot-Fletcher, M. C., Underwood, D. C., Breton, J. J., Adams, J. L., Kagey-Sobotka, A., Griswold, D. E., Marshall, L. A., Sarau, H. M., Winkler, J. D., Hay, D. W. P. (1995) Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthma. J. Pharmacol. Exp. Ther. 273: 1147-1155
6. Chang, Z. L., Fornnarino, J., Heathcote, D., Sasse, C., Shada, D., Thomsen, J., Wong, C. F., Norton, K. (1995) Hydrolytic degradation studies of zileuton. Pharm. Res. 12: S-60
7. Chung, K. F. (1995) Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur. Respir. J. 8: 1203-1213
8. Dean, F. M., Sargent, M. V. (1984) In: Bird, C. W., Cheeseman, G. W. H. (eds) Comprehensive Heterocyclic Chemistry. Pergamon Press, New York, 1984, p. 591
9. Ghosh, S., Datta, I., Chakraborty, R., Das, T. K., Sengupta, J., Sarkar, D. C. (1989) Studies on oxygen heterocycles Part 1: acid catalysed and photochemical reactions of some aryldiazoketones. Tetrahedron 45: 1441-1446
10. Kraus, G. A., Thomas, P. J., Schwinden, M. D. (1990) An approach to aflatoxins using type II photocyclization reactions. Tetrahedron Lett. 13: 1819-1822
11. Rouzer, C. A., Samuelsson, B. (1985) On the nature of the 5-lipoxygenase reaction in human leukocytes: enzyme purification and requirement for multiple stimulatory factors. Proc. Natl Acad. Sci. USA 82: 6040-6044
12. 4 synthase activities. Proc. Natl Acad. Sci. USA 83: 857-861
13. Teo, C. C., Kon, O. L., Sim, K. Y., Ng, S. C. (1992) Synthesis of 2-(p-chlorobenzyl)-3-aryl-6-methoxybenzofurans as selective ligands for antiestrogen-binding sites. Effects on cell proliferation and cholesterol synthesis. J. Med. Chem. 35: 1330-1339
14. Trivedi, J. S., Fort, J. J. (1995) Kinetics and degradation in aqueous solution of Abbott-79175, a potent second generation 5-lipoxygenase inhibitor. Int. J. Pharm. 123: 217-227